**Position Statement**

**BILLING/CODING**

**REIMBURSEMENT**

**Program Exceptions**

**Definitions**

**Related Guidelines**

**DESCRIPTION:**

Bone morphogenetic proteins (BMPs) are members of the family of transforming growth factors. At present, more than 20 different BMPs have been identified, all with varying degrees of tissue-stimulating properties.

The recombinant human bone morphogenetic proteins (rhBMPs) are delivered to the bone grafting site as part of a surgical procedure; a variety of carrier and delivery systems has been investigated. Carrier systems, which are absorbed over time, maintain the concentration of the rhBMP at the treatment site; provide temporary scaffolding for osteogenesis; and prevent extraneous bone formation. Carrier systems have included inorganic material, synthetic polymer, natural polymers, and bone allograft. The rhBMP and carrier may be inserted via a delivery system, which may also provide mechanical support.

The carrier and delivery system are important variables in the clinical use of rhBMPs, and different clinical applications have been evaluated with different carriers and delivery systems. For example, rhBMP putty with pedicle and screw devices are used for instrumented intertransverse fusion (posterolateral fusion), while rhBMP in a collagen sponge with bone dowels or interbody cages are used for interbody spinal fusion. In addition, interbody fusion of the lumbar spine can be approached from an anterior, lateral, or posterior direction. Surgical procedures may include decompression of the spinal canal and insertion of pedicle screws and rods to increase stability of the spine.

Posterior approaches allow decompression (via laminotomies and facetectomies) for treatment of spinal canal pathology (eg, spinal stenosis, lateral recess and foraminal stenosis, synovial cysts, hypertrophic ligamentum flavum) along with stabilization of the spine and are differentiated from instrumented or noninstrumented posterolateral fusion, which involves the transverse processes. Due to the proximity of these procedures to the spinal canal, risks associated with ectopic bone formation are increased (eg,
radiculopathies). Increased risk of bone resorption around rhBMP grafts, heterotopic bone formation, epidural cyst formation, and seromas has also been postulated.

**Regulatory Status**

The INFUSE® Bone Graft product (Medtronic) consists of rhBMP-2 on an absorbable collagen sponge carrier; it is used in conjunction with several carrier and delivery systems. The INFUSE® line of products has been approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process.

In 2008, the FDA issued a public health notification on life-threatening complications associated with rhBMP in cervical spine fusion. Complications were associated with swelling of neck and throat tissue, which resulted in compression of the airway and/or neurologic structures in the neck. Some reports described difficulty swallowing, breathing, or speaking. Severe dysphagia following cervical spine fusion using rhBMP products has also been reported in the literature. As stated in the public health notification, the safety and efficacy of rhBMP in the cervical spine have not been demonstrated. These products are not approved by the FDA for this use.

Recombinant human bone morphogenetic protein-7 (rhBMP-7) [e.g., OP-1® Putty (Stryker Biotech)], consists of rhBMP-7 and bovine collagen and carboxymethylcellulose, and forms a paste or putty when reconstituted with saline. The rhBMP-7 product is no longer marketed in the U. S.

**POSITION STATEMENT:**

Use of recombinant human bone morphogenetic protein-2 (rhBMP-2, InFUSE™) meets the definition of medical necessity in skeletally mature individuals for the following indications:

- For anterior lumbar interbody fusion procedures when the use of autograft is not feasible*, OR
- For instrumented posterolateral intertransverse spinal fusion procedures when the use of autograft is not feasible*, OR
- For the treatment of acute, open fracture of the tibial shaft, when the use of autograft is not feasible*

*NOTE: Use of autograft via iliac crest bone graft (ICBG) may be considered not feasible due to situations that may include, but are not limited to, prior harvesting of ICBG, or a need for a greater quantity of ICBG than is available (eg, for multilevel fusion).

Bone morphogenetic protein (rhBMP-2, InFUSE™) is considered experimental or investigational for all other indications, including but not limited to:

- Spinal fusions when the use of autograft is feasible
- Craniomaxillofacial surgeries

Recombinant human bone morphogenetic protein-7 [rhBMP-7, e.g., OP–1™] is considered experimental or investigational for all indications. There is a lack of clinical scientific evidence published in peer-reviewed literature to permit conclusions on safety and net health outcomes.

**BILLING/CODING INFORMATION:**

There is no specific CPT or HCPCS code for bone morphogenetic protein. In 2011, CPT code 20930 was revised to include BMP-type materials used in spine surgery.
LOINC Codes:
The following information may be required documentation to support medical necessity: Physician history and physical, initial assessment, procedure note, visit note.

<table>
<thead>
<tr>
<th>Documentation Table</th>
<th>LOINC Codes</th>
<th>LOINC Time Frame Modifier Code</th>
<th>LOINC Time Frame Modifier Codes Narrative</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician history and physical</td>
<td>28626-0</td>
<td>18805-2</td>
<td>Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.</td>
</tr>
<tr>
<td>Physician Initial Assessment</td>
<td>18736-9</td>
<td>18805-2</td>
<td>Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.</td>
</tr>
<tr>
<td>Physician procedure note</td>
<td>11505-5</td>
<td>18805-2</td>
<td>Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.</td>
</tr>
<tr>
<td>Attending physician visit note</td>
<td>18733-6</td>
<td>18805-2</td>
<td>Include all data of the selected type that represents observations made six months or fewer before starting date of service for the claim.</td>
</tr>
</tbody>
</table>

REIMBURSEMENT INFORMATION:
Refer to section entitled POSITION STATEMENT.

PROGRAM EXCEPTIONS:
Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products:
No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline reviewed date.

DEFINITIONS:
Autograft: a tissue (or an organ) transferred by grafting into a new position in the body of the same individual.

Morphogenetic (morphogenesis): the ability of a molecule or group of molecules to assume a certain shape; differentiation of cells and tissues in the early embryo that establishes the form and structure of the various organs and parts of the body.

Posterolateral: behind and to one side of, specifically to the outer side.

RELATED GUIDELINES:
None applicable.
OTHER:

Other index terms for bone morphogenetic protein:

Note: The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Morphogenic or morphogenetic protein-2
BMP-2
INFUSE® Bone Graft
INFUSE™ Bone Graft/LT-CAGE™ Lumbar Tapered Fusion Device
INFUSE™ Bone Graft/Medtronic Interbody Fusion Device

REFERENCES:


7. Blue Cross Blue Shield Association Medical Policy 7.01.100 Bone Morphogenetic Protein, (May 2019).


17. ECRI Health Technology Assessment. Interbody cage with bone morphogenetic protein for degenerative disc disease. (December 2003).

18. ECRI Target Report #849Osteogenic protein-1 (OP-1) for spinal fusion. (07/04).


26. Hayes Medical Technology Directory; “Recombinant Human Bone Morphogenetic Protein for Use In Bone Repair” (03/06/04).


COMMITTEE APPROVAL:
This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy & Coverage Committee on 07/25/19.

GUIDELINE UPDATE INFORMATION:

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/01/06</td>
<td>New Medical Coverage Guideline.</td>
</tr>
<tr>
<td>09/15/06</td>
<td>Scheduled review; expand coverage statement to include multiple level spinal fusions; remove non-coverage statement regarding multiple level spinal fusion procedures.</td>
</tr>
<tr>
<td>09/15/07</td>
<td>Scheduled review; typographical corrections were made; reformatted guideline; updated references.</td>
</tr>
<tr>
<td>07/15/08</td>
<td>Scheduled review; no change in position statement; references updated; guideline is moved to &quot;no longer scheduled for routine review&quot; status.</td>
</tr>
<tr>
<td>11/15/10</td>
<td>Reviewed and revised to clarify Position Statements; formatting changes; references updated.</td>
</tr>
<tr>
<td>09/15/11</td>
<td>Revision; formatting changes.</td>
</tr>
<tr>
<td>04/15/12</td>
<td>Scheduled review; Position Statement revised; references updated; formatting changes.</td>
</tr>
<tr>
<td>05/11/14</td>
<td>Revision: Program Exceptions section updated.</td>
</tr>
<tr>
<td>10/15/14</td>
<td>Revision: Billing and Coding Information section.</td>
</tr>
<tr>
<td>06/15/16</td>
<td>Scheduled review. Revised description section, Position Statement, and Billing/Coding Information section. Updated references. Reformatted guideline.</td>
</tr>
<tr>
<td>07/01/19</td>
<td>Revision: Deleted statements regarding anterior approach from the position statement section. Reformatted guideline.</td>
</tr>
<tr>
<td>08/15/19</td>
<td>Scheduled review. Revised description, position statement, definitions, and index terms. Updated references.</td>
</tr>
</tbody>
</table>